Treating older people

Special Article


  1. 1.
    Louria DB (2005) Extraordinary longevity: individual and societal issues. J Am Geriatr Soc 53:S317–S319PubMedCrossRefGoogle Scholar
  2. 2.
    Christensen K, Doblhammer G, Rau R, Vaupel JW (2009) Ageing populations: the challenges ahead. Lancet 374:1196–120PubMedCrossRefGoogle Scholar
  3. 3.
    UK Department of Health. Prescriptions dispensed in the community statistics for 1992–2002: England—prescription cost analysis 2002. Available at:
  4. 4.
    Van Spall HG, Toren A, Kiss A et al (2007) Eligibility criteria of randomised controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297:1233–1240PubMedCrossRefGoogle Scholar
  5. 5.
    Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone evaluation study. N Eng J Med 341:709–717CrossRefGoogle Scholar
  6. 6.
    Bozkurt B, Agoston I, Knowlton AA (2003) Complications of inappropriate use of spironolactone; when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41:211–214PubMedCrossRefGoogle Scholar
  7. 7.
    Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D (2003) Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure; retrospective study. Br Med J 327:1141–1142CrossRefGoogle Scholar
  8. 8.
    Dinsdale C, Wani M, Steward J, O’Mahony MS (2005) Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. Age Ageing 34:395–398PubMedCrossRefGoogle Scholar
  9. 9.
    Castleden CM, Pickles H (1988) Suspected adverse drug reactions in elderly patients reported to the committee on safety of medicines. Br J Chn Pharmacol 26:347–353CrossRefGoogle Scholar
  10. 10.
    Mannesse CK, Derkx FH, de Ridder MA, de Man in ’t Veld AJ, van der Cammen TJ (1997) Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. Br Med J 315:1057–1058CrossRefGoogle Scholar
  11. 11.
    The American Geriatrics Society (2012) Beers criteria update expert panel. American geriatrics society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:616–631CrossRefGoogle Scholar
  12. 12.
    Somers E, Simmonds D, Whitelaw C, Calver J, Beer C (2010) Quality use of medicines in residential aged care. Aust Fam Phys 39:413–416Google Scholar
  13. 13.
    Willcox SM, Himmelstein DU, Woolhandler S (1994) Inappropriate drug prescribing for the community-dwelling elderly. JAMA 272:292–296PubMedCrossRefGoogle Scholar
  14. 14.
    Gallagher PF, Barry PJ, Ryan C, Hartigan I, O’Mahony D (2008) Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers’ Criteria. Age Ageing 37:96–101qPubMedCrossRefGoogle Scholar
  15. 15.
    Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Reglat A (2005) Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol 59:143–151PubMedCrossRefGoogle Scholar
  16. 16.
    Stephen PJ, Williamson J (1984) Drug induced parkinsonism in the elderly. Lancet ii:1082–1083CrossRefGoogle Scholar
  17. 17.
    Sorock GS, Shimkin EE (1988) Use of benzodiazepine sedatives and risk of falling in a community- dwelling elderly cohort. Arch Intern Med 148(11):2441–2444PubMedCrossRefGoogle Scholar
  18. 18.
    Cusack BJ (2004) Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2:274–302PubMedCrossRefGoogle Scholar
  19. 19.
    Mangoni AA, Jackson SHD (2003) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6–14CrossRefGoogle Scholar
  20. 20.
    Currie GM, Wheat JM, Kiat H (2011) Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J 5:130–135PubMedCrossRefGoogle Scholar
  21. 21.
    Gainsborough N, Maskrey VL, Nelson ML, Keating J, Sherwood RA, Jackson SH, Swift CG (1993) The association of age with gastric emptying. Age Ageing 22:37–40PubMedCrossRefGoogle Scholar
  22. 22.
    Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW (2009) Inflammation and frailty measures in older people. J Cell Mol Med 13:3103–3109PubMedCrossRefGoogle Scholar
  23. 23.
    Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K (2010) Frailty, body mass index, and abdominal obesity in older people. J Gerontol A Biol Sci Med Sci 65(4):377–381PubMedCrossRefGoogle Scholar
  24. 24.
    Sheldon JH (1963) The effect of age on the control of sway. Gerontol Clin 5:129CrossRefGoogle Scholar
  25. 25.
    Robertson DRC, Waller DG, Renwick AC, George CF (1988) Age related changes in the pharmacokinetics and pharmacodynamics of nifedepine. Br jf Clin Pharmacol 25:297–305CrossRefGoogle Scholar
  26. 26.
    Rowe JW, Andres R, Tobin JD, Norris AM, Shock NW (1976) The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31:155–163PubMedCrossRefGoogle Scholar
  27. 27.
    Lindeman RD, Tobin J, Shock NW (1985) Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33:278–285PubMedGoogle Scholar
  28. 28.
    Wynne HA, Cope LH, James OFW, Rawlins MD, Woodhouse KW (1989) The effect of age and frailty upon acetanilide clearance in man. Age Ageing 18:415–418PubMedCrossRefGoogle Scholar
  29. 29.
    Wynne HA, Cope L, Herd B, James OFW, Rawlins MD, Woodhouse KW (1990) The association of age and frailty with paracetamol conjugation in man. Age Ageing 19:419–424PubMedCrossRefGoogle Scholar
  30. 30.
    Wynne HA, Yelland C, Cope LH, Boddy A, Woodhouse KW, Bateman DN (1993) The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 22:354–359PubMedCrossRefGoogle Scholar
  31. 31.
    Woodhouse KW, Wynne H, Baillie S, James O, Rawlins MD (1988) Who are the frail elderly? QJM 68:505–506PubMedGoogle Scholar
  32. 32.
    Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol Biol Med Sci 56:M146–M156CrossRefGoogle Scholar
  33. 33.
    Hubbard RE, O’Mahony MS, Woodhouse KW (2009) Character- ising frailty in the clinical setting—a comparison of different approaches. Age Ageing 38:115–119PubMedCrossRefGoogle Scholar
  34. 34.
    Rockwood K, Mitnitski A (2007) Frailty in relation to the accu- mulation of deficits. J Gerontol A Biol Sci Med Sci 62:722–727PubMedCrossRefGoogle Scholar
  35. 35.
    Eeles EMP, White SV, O’Mahony MS, Bayer AJ, Hubbard RE (2012) The impact of frailty and delirium on mortality in older inpatients. Age Ageing 41(3):412–416PubMedCrossRefGoogle Scholar
  36. 36.
    Singh I, Davis K, Gallacher J, Johansen A, Eeles EMP, Hubbard RE (2012) Predictors of adverse outcome on an acute geriatric rehabilitation ward. Age Ageing 41:242–246PubMedCrossRefGoogle Scholar
  37. 37.
    Abou-Hatab K, O’Mahony MS, Patel S, Woodhouse K (2001) Relationship between age and plasma esterases. Age Ageing 30(1):41–45PubMedCrossRefGoogle Scholar
  38. 38.
    Hubbard R, O’Mahony MS, Woodhouse K (2012) Medication prescribing in frail older people. Eur J Clin Pharmacol doi:10.1007/s00228-012-1387-2

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Geriatric Medicine, Cardiff University Academic Centre, Floor 3University Hospital Llandough, LlandoughVale of GlamorganUK

Personalised recommendations